Comments
GVK Biosciences has entered into a collaboration agreement with the US-based Endo Pharmaceuticals for discovering novel small molecules targeting a protein.
Under this agreement GVK Bio will use its discovery expertise to deliver a clinical candidate and Endo will develop and commercialise the product arising out of this collaboration.
The Hyderabad-based company recently launched a new initiative called Early Discovery Assets. The early stage asset portfolio is focussed around pain and inflammation. It is about building a set of project assets for potential early stage partnerships.
Manni Kantipudi, CEO of the company said, "The partnership with Endo is a continuation to build discovery pipeline through external collaborations."
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.